home / stock / rvv:cc / rvv:cc news

RVV:CC News and Press, Revive Therapeutics Ltd - Ordinary Shares From 11/30/22

Stock Information
Company Name: Revive Therapeutics Ltd - Ordinary Shares
Stock Symbol: RVV:CC
Market: CNQC
Website: revivethera.com
Menu
RVV:CC RVV:CC Quote RVV:CC Short RVV:CC News RVV:CC Articles RVV:CC Message Board
Get RVV:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
RVV:CC - Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“ Revive ” or the “ Company ”) is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of units (each, a &...
RVV:CC - Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorde...

RVV:CC - Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorde...

RVV:CC - Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorde...
RVV:CC - Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disord...

RVV:CC - CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Toronto, Ontario--(Newsfile Corp. - Le 15 septembre 2022/September 2022) - The quarterly rebalancing of the CSE 25 Index will result in the following changes, effective after the close on Friday, September 16, 2022. Le rééquilibrage trimestriel de l’indice composé du ...

RVV:CC - Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disord...
RVV:CC - Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmun...

RVV:CC - PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders ...

RVV:CC - Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disord...
Previous 10 Next 10